5-year results for pembrolizumab treatment of advanced melanoma

Affiliations

¹ Section of DermatoOncology, Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany. Electronic address: jessica.hassel@med.uni-heidelberg.de.

Comment

Jessica C Hassel. Lancet Oncol. 2019 Sep.

. 2019 Sep;20(9):1187-1189.

doi: 10.1016/S1470-2045(19)30483-8. Epub 2019 Jul 22.

¹ Section of DermatoOncology, Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany. Electronic address: jessica.hassel@med.uni-heidelberg.de.

No abstract available

Comment on

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Robert C, et al. Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345627 Clinical Trial.